344 related articles for article (PubMed ID: 36969352)
1.
Ibrahim A; Chattaraj A; Iqbal Q; Anjum A; Rehman MEU; Aijaz Z; Nasir F; Ansar S; Zangeneh TT; Iftikhar A
Avicenna J Med; 2023 Jan; 13(1):23-34. PubMed ID: 36969352
[No Abstract] [Full Text] [Related]
2. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
3. Pneumocystis jirovecii: a review with a focus on prevention and treatment.
Weyant RB; Kabbani D; Doucette K; Lau C; Cervera C
Expert Opin Pharmacother; 2021 Aug; 22(12):1579-1592. PubMed ID: 33870843
[No Abstract] [Full Text] [Related]
4. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.
Salzer HJF; Schäfer G; Hoenigl M; Günther G; Hoffmann C; Kalsdorf B; Alanio A; Lange C
Respiration; 2018; 96(1):52-65. PubMed ID: 29635251
[TBL] [Abstract][Full Text] [Related]
5. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
6. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
Helweg-Larsen J; Benfield T; Atzori C; Miller RF
J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.
Ghembaza A; Vautier M; Cacoub P; Pourcher V; Saadoun D
Chest; 2020 Dec; 158(6):2323-2332. PubMed ID: 32502592
[TBL] [Abstract][Full Text] [Related]
10. Veno-Venous Extracorporeal Membrane Oxygenation for Severe Pneumocystis jirovecii Pneumonia in an Immunocompromised Patient without HIV Infection.
Nureki SI; Usagawa Y; Watanabe E; Takenaka R; Shigemitsu O; Abe T; Yasuda N; Goto K; Kitano T; Kadota JI
Tohoku J Exp Med; 2020 Apr; 250(4):215-221. PubMed ID: 32249237
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation.
Brakemeier S; Pfau A; Zukunft B; Budde K; Nickel P
Pharmacol Res; 2018 Aug; 134():61-67. PubMed ID: 29890253
[TBL] [Abstract][Full Text] [Related]
12. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.
Quinn M; Fannin JT; Sciasci J; Bragg A; Campbell PK; Carias D; Crews KR; Gregornik D; Jeha S; Maron G; Pauley JL; Swanson HD; Wolf J; Greene W
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866879
[No Abstract] [Full Text] [Related]
13. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
14. Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing.
Huang L; Xu S; Huang Z; Chen Y; Xu N; Xie B
BMC Pulm Med; 2023 Feb; 23(1):72. PubMed ID: 36829171
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
16. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
Sidhu VK; Foisy MM; Hughes CA
Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
[TBL] [Abstract][Full Text] [Related]
17. Clinical descriptive analysis of severe
Xie D; Xu W; You J; Yuan X; Li M; Bi X; Zhang K; Li H; Xian Y
Bioengineered; 2021 Dec; 12(1):1264-1272. PubMed ID: 33896387
[No Abstract] [Full Text] [Related]
18. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease-a Case Series.
Vieujean S; Moens A; Hassid D; Rothfuss K; Savarino EV; Vavricka SR; Reenaers C; Jacobsen BA; Allez M; Ferrante M; Rahier JF
J Crohns Colitis; 2023 Apr; 17(4):472-479. PubMed ID: 36223253
[TBL] [Abstract][Full Text] [Related]
19. Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review.
Grewal P; Brassard A
J Cutan Med Surg; 2009; 13(6):308-12. PubMed ID: 19919808
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.
Basiaga ML; Ross ME; Gerber JS; Ogdie A
J Pediatric Infect Dis Soc; 2018 Dec; 7(4):283-289. PubMed ID: 28992298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
